Safety, efficacy, tolerability and pharmacokinetics of NNC 0070-0002-0182 in overweight or obese healthy male volunteers.
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2016
At a glance
- Drugs NNC 0070-0002-0182 (Primary)
- Indications Obesity
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 16 Oct 2009 Actual patient number amended from 60 to 101 as reported by ClinicalTrials.gov.
- 16 Oct 2008 Actual patient number (60) added as reported by ClinicalTrials.gov.